OncoMatch/Clinical Trials/NCT04084717
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
Is NCT04084717 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Crizotinib for non-squamous non-small-cell lung cancer.
Treatment: Crizotinib — This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer. Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ROS1 rearrangement
documented ROS1 rearrangement (cohort 1)
Required: MET exon 14
MET-activating mutation (exon 14) (cohort 2)
Required: MET amplification
MET-amplification (cohort 3)
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Had chemotherapy (including investigational cytotoxic chemotherapy) within 4 weeks prior to the proposed first dose of study treatment
Cannot have received: biologic agent
biologic agents (e.g. targeted therapy or antibodies) within 4 weeks prior to the proposed first dose of study treatment
Cannot have received: radiation therapy
radiotherapy within 2 weeks prior to the proposed first dose of study treatment
Lab requirements
Blood counts
adequate hematologic function within 7 days of the proposed start date of treatment
Kidney function
adequate organ function within 7 days of the proposed start date of treatment
Liver function
adequate organ function within 7 days of the proposed start date of treatment
Cardiac function
adequate cardiac function within 28 days of the proposed start date of treatment
Adequate hematologic and organ function within 7 days of the proposed start date of treatment and adequate cardiac function within 28 days of the proposed start date of treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04084717 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cytotoxic chemotherapy, biologic agent, radiation therapy disqualifies patients from enrollment.
Does this trial require ROS1?
Yes, ROS1 rearrangement is a required biomarker for enrollment.
Does this trial require MET?
Yes, MET exon 14 is a required biomarker for enrollment.
Does this trial require MET?
Yes, MET amplification is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify